| 1. |
Sverzellati N, Lynch DA, Hansell DM, et al. American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. Radiographics, 2015, 35(7): 1849-1871.
|
| 2. |
Yalniz E, Polat G, Demirci F, et al. Are idiopathic pulmonary fibrosis patients more anxious and depressive than patient's with other interstitial lung disease?. Sarcoidosis Vasc Diffuse Lung Dis, 2019, 36(4): 294-301.
|
| 3. |
Zhou YH, Mak YW. Psycho-physiological associates of dyspnea in hospitalized patients with interstitial lung diseases: a cross-sectional study. Int J Environ Res Public Health, 2017, 14(10): 1277.
|
| 4. |
Carvajalino S, Reigada C, Johnson MJ, et al. Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review. BMC Pulm Med, 2018, 18(1): 78.
|
| 5. |
Tzouvelekis A, Karampitsakos T, Kourtidou S, et al. Impact of depression on patients with idiopathic pulmonary fibrosis. Front Med (Lausanne), 2020, 7: 29.
|
| 6. |
Deniz S, ?ahin H, Yalniz E. Does the severity of interstitial lung disease affect the gains from pulmonary rehabilitation?. Clin Respir J, 2018, 12(6): 2141-2150.
|
| 7. |
Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med, 2014, 108(1): 203-210.
|
| 8. |
Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest, 2009, 135(2): 442-447.
|
| 9. |
Lee YJ, Choi SM, Lee YJ, et al. Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis. PLoS One, 2017, 12(9): e0184300.
|
| 10. |
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest, 2011, 139(3): 609-616.
|
| 11. |
Holland AE, Fiore JF, Jr., Bell EC, et al , Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology, 2014, 19(8): 1215-1221.
|
| 12. |
Ryerson CJ, Arean PA, Berkeley J, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology, 2012, 17(3): 525-532.
|
| 13. |
Coelho AC, Knorst MM, Gazzana MB, et al. Predictors of physical and mental health-related quality of life in patients with interstitial lung disease: a multifactorial analysis. J Bras Pneumol, 2010, 36(5): 562-570.
|
| 14. |
Akhtar AA, Ali MA, Smith RP. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis, 2013, 10(3): 127-133.
|
| 15. |
Glaspole IN, Watson AL, Allan H, et al. Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. Eur Respir J, 2017, 50(2): 1700168.
|
| 16. |
Van Manen MJ, Kreuter M, Van Den Blink B, et al. What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. ERJ Open Res, 2017, 3(1): 00065-2016.
|
| 17. |
Kreuter M, Swigris J, Pittrow D, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res, 2019, 20(1): 59.
|
| 18. |
Kreuter M, Bendstrup E, Russell AM, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med, 2017, 5(12): 968-980.
|
| 19. |
King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med, 2017, 5(1): 72-84.
|
| 20. |
De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J, 2001, 17(5): 954-961.
|
| 21. |
Holland AE, Hill CJ, Glaspole I, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med, 2012, 106(3): 429-435.
|
| 22. |
Yuan XY, Zhang H, Huang LR, et al. Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases. PLoS One, 2020, 15(7): e0236346.
|
| 23. |
Matsuda T, Taniguchi H, Ando M, et al. Depression is significantly associated with the health status in patients with idiopathic pulmonary fibrosis. Intern Med, 2017, 56(13): 1637-1644.
|
| 24. |
Yohannes AM, Newman M, Kunik ME. Psychiatric collaborative care for patients with respiratory disease. Chest, 2019, 155(6): 1288-1295.
|
| 25. |
Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med, 2006, 173(12): 1390-1413.
|
| 26. |
Blakemore A, Dickens C, Guthrie E, et al. Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis, 2014, 9: 501-512.
|
| 27. |
Thoma N, Pilecki B, Mckay D. Contemporary cognitive behavior therapy: a review of theory, history, and evidence. Psychodyn Psychiatry, 2015, 43(3): 423-461.
|
| 28. |
Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci, 2017, 19(2): 93-107.
|
| 29. |
Zhang XM, Yin CC, Tian WG, et al. Effects of cognitive behavioral therapy on anxiety and depression in patients with chronic obstructive pulmonary disease: a meta-analysis and systematic review. Clin Respir J, 2020, 14(10): 891-900.
|
| 30. |
Williams MT, Johnston KN, Paquet C. Cognitive behavioral therapy for people with chronic obstructive pulmonary disease: rapid review. Int J Chron Obstruct Pulmon Dis, 2020, 15: 903-919.
|
| 31. |
Lovell N, Bajwah S, Maddocks M, et al. Use of mirtazapine in patients with chronic breathlessness: a case series. Palliative Med, 2018, 32(9): 1518-1521.
|
| 32. |
Higginson IJ, Wilcock A, Johnson MJ, et al. Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). Thorax, 2020, 75(2): 176-179.
|
| 33. |
Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev, 2016, 10(10): CD007354.
|
| 34. |
Genberg J, Davies JM, Ahmadi Z, et al. Indications and patterns of use of benzodiazepines and opioids in severe interstitial lung disease: a population-based longitudinal study. ERJ Open Res, 2021, 7(1): 00716-2020.
|
| 35. |
Bajwah S, Davies JM, Tanash H, et al. Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. Eur Respir J, 2018, 52(6): 1801278.
|
| 36. |
Liao YH, Chen LY, Liao KM, et al. Drug safety of benzodiazepines in Asian patients with chronic obstructive pulmonary disease. Front Pharmacol, 2020, 11: 592910.
|
| 37. |
Rosenberg T, Lattimer R, Montgomery P, et al. The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case-control study. Clin Interv Aging, 2017, 12: 1977-1984.
|
1/5
WeChat